Inspire Medical Systems (INSP) Tops Q4 EPS by 43c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Inspire Medical Systems (INSP) PT Lowered to $220 at Morgan Stanley
February 11, 2025 7:09 AM ESTMorgan Stanley analyst Kallum Titchmarsh lowered the price target on Inspire Medical Systems (NYSE: INSP) to $220.00 (from $230.00) while maintaining a Overweight rating.
The analyst comments "A good way for INSP to close out the year with profitability coming in comfortably ahead. Both existing... More
Inspire Medical Systems (INSP) PT Raised to $194 at Leerink Partners
February 11, 2025 6:32 AM ESTLeerink Partners analyst Mike Kratky raised the price target on Inspire Medical Systems (NYSE: INSP) to $194.00 (from $193.00) while maintaining a Market Perform rating.
The analyst comments "Bottom Line: We are bumping up our price target on INSP to $194 (from $193) to reflect our updated model and slightly lower share count following the company's 4Q24 earnings. However, we are... More
